Cadrenal Therapeutics, Inc. CVKD
1.15
(0.05)
(4.17%)
as of 25 Sep
- Market cap
- $4.3M
- P/E
- 0.0×
Follow CVKD
| Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|
Current Ratio |
0.55 | 10.27 | 3.77 | 2.72 |
Net Debt/EBITDA |
(0.20) | 1.10 | 0.91 | 0.30 |
Debt/Assets |
71.10% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
(0.10) | 0.00 | 0.00 | 0.00 |
Asset Turnover |
— | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.18 | 0.42 | 0.69 | 0.95 |
Capex/Depreciation |
(0.03) | (0.21) | (3.42) | (0.74) |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 |
| 0.00% | (780.60%) | (140.78%) | (260.11%) | |
| 0.00% | (179.77%) | (114.27%) | (183.21%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
1,108.15% | (108.99%) | (143.25%) | (483.72%) |
Average Days of Receivables |
— | 0.00 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% |
Free Cash Flow per Share |
(2.29) | (3.93) | (6.04) | (6.32) |
Cash per Share |
0.06 | 9.34 | 8.21 | 2.01 |
Shareholders Equity per Share |
(10.55) | 8.55 | 6.10 | 1.37 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(10.55) | 8.55 | 6.10 | 1.37 |
Free Cash Flow |
(1.21) | (3.53) | (7.36) | (12.61) |
Working Capital |
(0.61) | 7.67 | 7.43 | 2.73 |
Capital Expenditures |
0.00 | 0.00 | (0.01) | (0.01) |
Net Current Asset Value |
(5.60) | 7.67 | 7.43 | 2.73 |
| Other line items | ||||
Quick Ratio |
0.02 | 10.21 | 3.75 | 2.53 |
Depreciation/Fixed assets |
68.20 | 6.74 | 0.28 | 1.33 |
Cash ROIC |
24.28% | (21.95%) | (42.19%) | (186.87%) |
Accounts Receivable Turnover |
— | — | 0.00 | 0.00 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
0.00 | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
0.00 | — | — | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(2.29) | (3.92) | (6.03) | (6.32) |
Capex per Share |
0.00 | 0.00 | (0.01) | 0.00 |
Average Receivables |
— | — | 0.04 | 0.02 |
Average Payables |
— | 0.29 | 0.83 | 1.08 |
Average Assets |
— | 4.65 | 9.32 | 7.23 |
Average Common Equity |
— | 1.07 | 7.57 | 5.09 |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates